Cargando…

Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis

BACKGROUND: Aberrant brain insulin signaling has been posited to lie at the crossroads of several metabolic and cognitive disorders. Intranasal insulin (INI) is a non-invasive approach that allows investigation and modulation of insulin signaling in the brain while limiting peripheral side effects....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Sally, Stogios, Nicolette, Hahn, Margaret, Navagnanavel, Janani, Emami, Zahra, Chintoh, Araba, Gerretsen, Philip, Graff-Guerrero, Ariel, Rajji, Tarek K., Remington, Gary, Agarwal, Sri Mahavir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306194/ https://www.ncbi.nlm.nih.gov/pubmed/37379265 http://dx.doi.org/10.1371/journal.pone.0286887

Ejemplares similares

Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
por: Stogios, Nicolette, et al.
Publicado: (2021)

Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls
por: Stogios, Nicolette, et al.
Publicado: (2022)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)

S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS
por: Costa-Dookhan, Kenya, et al.
Publicado: (2020)

M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY
por: Mahavir Agarwal, Sri, et al.
Publicado: (2020)

Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023)

Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review
por: Stogios, Nicolette, et al.
Publicado: (2020)

Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia
por: Costa-Dookhan, Kenya A., et al.
Publicado: (2021)

Non-invasive neuromodulation of dorsolateral prefrontal cortex to reduce craving in alcohol use disorder: A meta-analysis
por: Sorkhou, Maryam, et al.
Publicado: (2022)

Favourable cognitive changes observed with metabolic improvements in a patient with severe mental illness
por: van Reekum, Emma A, et al.
Publicado: (2023)

S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE
por: Agarwal, Sri Mahavir, et al.
Publicado: (2020)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study
por: Lee, Jiwon, et al.
Publicado: (2023)

Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D(2/3) Receptors in the Ventral Striatum of Healthy Nonobese Humans
por: Caravaggio, Fernando, et al.
Publicado: (2015)

The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
por: Raben, Alex T., et al.
Publicado: (2018)

Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol
por: Agarwal, Sri Mahavir, et al.
Publicado: (2023)

Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity
por: Gerretsen, Philip, et al.
Publicado: (2019)

Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia
por: Davies, Simon JC, et al.
Publicado: (2018)

S225. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OR PREVENTION OF WEIGHT GAIN IN SCHIZOPHRENIA
por: Agarwal, Sri Mahavir, et al.
Publicado: (2018)

Editorial: Cardiovascular and Physical Health in Severe Mental Illness
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

Intranasal Insulin for Alzheimer’s Disease
por: Hallschmid, Manfred
Publicado: (2021)

A Comprehensive Review of Intranasal Insulin and Its Effect on the Cognitive Function of Diabetics
por: Gaddam, Mrunanjali, et al.
Publicado: (2021)

Intranasal insulin neuroprotection in ischemic stroke
por: Lioutas, Vasileios-Arsenios, et al.
Publicado: (2016)

Metabolic Syndrome in Schizophrenia: Theoretical, Clinical and Translational Perspectives
por: Agarwal, Sri Mahavir, et al.
Publicado: (2013)

Physical health among people with serious mental illness in the face of COVID-19: Concerns and mitigation strategies
por: Melamed, Osnat C., et al.
Publicado: (2020)

The role of insulin sensitivity and intranasally applied insulin on olfactory perception
por: Edwin Thanarajah, Sharmili, et al.
Publicado: (2019)

Intranasal Insulin Ameliorates Experimental Diabetic Neuropathy
por: Francis, George, et al.
Publicado: (2009)

Targeting Mediators of Smoking Persistence with Intranasal Insulin
por: Hamidovic, Ajna
Publicado: (2017)

Intranasal insulin in Alzheimer’s disease: Food for thought
por: Chapman, Colin D., et al.
Publicado: (2018)

F178. NEUROANATOMICAL PROFILES OF TREATMENT-RESISTANCE IN PATIENTS WITH SCHIZOPHRENIA
por: Plitman, Eric, et al.
Publicado: (2018)

S16. GLUTAMATERGIC NEUROMETABOLITE LEVELS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA: A CROSS-SECTIONAL 3T PROTON MRS STUDY
por: Iwata, Yusuke, et al.
Publicado: (2018)

Vaccine Hesitancy Is a Barrier to Achieving Equitable Herd Immunity Among Racial Minorities
por: Gerretsen, Philip, et al.
Publicado: (2021)

S175. AMOTIVATION IS ASSOCIATED WITH SMALLER VENTRAL STRIATUM VOLUMES IN OLDER PATIENTS WITH SCHIZOPHRENIA
por: Caravaggio, Fernando, et al.
Publicado: (2018)

Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia
por: Kim, Julia, et al.
Publicado: (2023)

Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia
por: Iwata, Yusuke, et al.
Publicado: (2021)

Differential Methylation Analysis of Suicidal Ideation Severity in Schizophrenia with the Illumina MethylationEPIC Array
por: Wang, Kevin Z., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qvcqlqt43lddo8v5ts6eimr7i8